S227928
- Generic Name
- S227928
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Phase 1
Recruiting
- Conditions
- Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)/AMLChronic Myelomonocytic Leukemia (CMML)
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 132
- Registration Number
- NCT06563804
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸The University of Kansas, Fairway, Kansas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath